TSC2 and neoplasm: The proportion of PD-L1high/CD8Ahigh was 41.4% in the TSC2low group, significantly higher than the 28.2% in the TSC2high group (P < 0.01; Fig. 4F), indicating that TSC2-loss tumor displayed an inflamed TME, which had been demonstrated to be associated with benefits from immunotherapy (9, 10).